ReviewInfectious disease clinics of North America2015
Fecal microbiota transplantation for the management of Clostridium difficile infection.
Review in Infectious disease clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Lactiplantibacillus plantarum GMNL-661 Ameliorates Clostridioides difficile Infection and Reconfigures Intestinal Microbiota in a Murine Model.Probiotics and antimicrobial proteins · 2025Article
- Suppressive Antibiotic Therapy in Prosthetic Joint Infections: A Contemporary Overview.Antibiotics (Basel, Switzerland) · 2025Review
- Reevaluating Biota Alteration: Reframing Environmental Influences on Chronic Immune Disorders and Exploring Novel Therapeutic Opportunities.The Yale journal of biology and medicine · 2024Review
- Article
- Tobramycin Nanoantibiotics and Their Advantages: A Minireview.International journal of molecular sciences · 2022Review
- In Vitro and In Vivo Anti-Journal of microbiology and biotechnology · 2022Article
- Successful use of early, repeat fecal microbiota transplantation for initial treatment of severe, refractory Clostridioides difficile colitis.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2021Article
- Suppressive Antibiotic Treatment in Prosthetic Joint Infections: A Perspective.Antibiotics (Basel, Switzerland) · 2021Review
- Primary Human Dendritic Cells and Whole-Blood Based Assays to Evaluate Immuno-Modulatory Properties of Heat-Killed Commensal Bacteria.Vaccines · 2021Article
- Health economic evaluations comparing faecal microbiota transplantation with antibiotics for treatment of recurrent Clostridioides difficile infection: a systematic review.Health economics review · 2021Review
- Clinical characteristics influence cultivable-bacteria composition in the meconium of Indonesian neonates.Heliyon · 2020Article
- A probiotic yeast-based immunotherapy againstScience translational medicine · 2020Article
- Chronic Inflammatory Diseases: Are We Ready for Microbiota-based Dietary Intervention?Cellular and molecular gastroenterology and hepatology · 2019Review
- Potential relevance of pig gut content transplantation for production and research.Journal of animal science and biotechnology · 2019Review
- Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis.Frontiers in microbiology · 2019Review
- Microbiota of MR1 deficient mice confer resistance against Clostridium difficile infection.PloS one · 2019Article
- Article
- Gut microbiome and aging: Physiological and mechanistic insights.Nutrition and healthy aging · 2018Review
- Clostridium difficile cure with fecal microbiota transplantation in a child with Pompe disease: a case report.Journal of medical case reports · 2018Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This article discusses the use of fecal microbiota transplantation (FMT) for the treatment of recurrent Clostridium difficile infection (CDI). The disruption of the normal gut microbiota is central to the pathogenesis of CDI, and disruption persists in recurrent disease. The use of FMT for recurrent CDI is characterized by a high response rate and short term safety is excellent, although the long-term effects of FMT are as yet unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.